Malian executive Chirfi Guindo, Merck & Co.’s chief Marketing Officer, was awarded a $13.74-million compensation package in 2022 — this reflects his contributions to talent development, fostering innovative public-private partnerships, and elevating Merck’s profile as a health group.
As a top Black executive in the health sector, Guindo earned a $0.35-million base salary, a $0.53-million performance-based short-term incentive, and a $12.39-million long-term incentive, reflecting his significant impact on Merck’s financial performance and executive influence.
Chirfi Guindo’s visionary leadership in Merck’s human health arena
Merck & Co., established in 1891, and based in New Jersey, experienced significant success in 2022. The company recorded a 15.75-percent growth in global sales, reaching $59.3 billion. This financial performance propelled Merck & Co. to the 69th position on the Fortune 500 list.
Guindo, with more than 25 years of experience, oversees long-term global strategies for Merck’s Human Health portfolio, encompassing oncology, vaccines, pharmaceuticals, and pipeline products. Formerly, he served as the Executive Vice President and Head of Global Product Strategy and Commercialization at Biogen.
Guindo’s unwavering dedication evident in his $2.1 million stake in Merck & Co.
With Guindo’s contribution as an executive, Merck’s profits surged by an impressive 84.65 percent, reaching $13.05 billion in 2022 from $7.08 billion in 2021. Net income and revenue also saw significant increases, reaching $14.52 billion and $59.3 billion, respectively.
Additionally, Merck’s assets expanded by 3.28 percent to $109.2 billion in fiscal year 2022. Highlighting Guindo’s commitment to Merck’s success, he maintains a personal stake in the company, owning a 0.0008-percent minority stake equivalent to 20,406 ordinary shares valued at $2.19 million.
His pivotal role in Merck & Co.’s remarkable financial achievements underscores his importance as a key figure in the pharmaceutical industry, contributing to innovation and industry growth.
